Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma

References

• “Cancer stat facts: kidney and renal pelvis cancer.” SEER, Available from: seer.cancer.gov/statfacts/html/kidrp.html.
   Google Scholar
• American Cancer Society, Kidney Cancer (adult)– renal cell carcinoma. Available from: (http://www.cancer.org/cancer/kidneycancer/detailedguide/).
   Google Scholar
• Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–1320.
   PubMed Web of Science ®Google Scholar
• Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol. 2004;287(1):F1–F6.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009;69(11):4674–4681.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Sorafenib NDA 21-923 approval letter, 12/ 20/2005. cited 2018 Oct 10 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021923_s000_Nexavar_Approv.pdf
   Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Sorafenib NDA 21-968 approval letter, [ updated 2006 Jan 26; cited 2018 Oct 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_Approv.pdf
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–5212.
   PubMed Web of Science ®Google Scholar
• Hall PS, Harshman LC, Srinivas S, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72–78.
   PubMed Web of Science ®Google Scholar
• Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084–1089.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Pazopanib NDA 022465 approval letter. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_Approv.pdf
   Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807): 1931–1939. Phase 3 AXIS trial showing axitinib was superior to sorafenib for treatment of advanced RCC in the second-line setting.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–562.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–2697.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–597.
   PubMed Web of Science ®Google Scholar
• Buti S, Bersanelli M. Is cabozantinib really better than sunitinib as first-line treatment of metastatic renal cell Carcinoma? J Clin Oncol. 2017;35(16):1858–1859.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–125.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Cabozantinib NDA 208692 approval letter. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000TOC.cfm
   Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–3799.
   PubMed Web of Science ®Google Scholar
• Molina AM, Hutson TE, Nosov D, et al. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. Eur J Cancer. 2018;94:87–94.
   PubMed Web of Science ®Google Scholar
• Fotivda. (n.d.). [cited 2018 Oct 10], from https://www.ema.europa.eu/medicines/human/EPAR/fotivda
   Google Scholar
• Jamil MO, Hathaway A, Mehta A. Tivozanib: status of development. Curr Oncol Rep. 2015;17(6):24.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Lenvatinib NDA 206947/S-003 approval letter. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000TOC.cfm
   Google Scholar
• Choueiri TK, Fay AP, Gray KP, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–2184.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757–1761.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the checkmate 016 study. J Immunother Cancer. 2018;6(1):109.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell Carcinoma (mRCC). J clin oncol. 2018;36(6_suppl):578.
   Web of Science ®Google Scholar
• Kelsey R. Kidney cancer: PDL1 as a biomarker in high-risk RCC. Nat Rev Urol. 2018;15(4):202.
   Google Scholar
• Choueiri TK, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19(4):451–460.
   PubMed Web of Science ®Google Scholar
• Motzer et al. Abstract LBA6_PR ‘JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)’ will be presented by Robert Motzer during Presidential Symposium 2 on Sunday 21 October, 16:30 to 18: 10(CEST) in room 18 - hall A2. Ann Oncol. 8 October 2018; 29 Supplement.
   Google Scholar
• Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405–415.
   PubMed Web of Science ®Google Scholar
• Rexer H, Bedke J. First-line therapy in advanced renal cell carcinoma: A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO. Urologe A. 2017;56(3):385–386.
   PubMedGoogle Scholar
• Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma. (2018, Oct 18). [cited 2018 Oct 20]. Available from: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pfizers-Inlyta-axitinib-Significantly-Improved-Overall-Survival-OS-and-Progression-free-Survival-PFS-as-First-Line-Therapy-for-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx
   Google Scholar
• Lee C, Makker V, Rasco DW, et al. Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results. Jco. 2018;36(15_suppl):4560.
   Google Scholar
• Motzer RJ, Grünwald V, Hutson TE, et al. A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma. Jco. 2018;36(6_suppl):TPS706–TPS706.
   Web of Science ®Google Scholar
• Nadal RM, Mortazavi A, Stein M, et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. Jco. 2018;36(6_suppl):515.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Apolo AB, Powles T, et al. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). Jco. 2018;36(15_suppl):TPS4598–TPS4598.
   Web of Science ®Google Scholar
• Maia MC, Agarwal N, McGregor BA, et al. Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC). JCO. 2018;36(5_suppl):TPS42–TPS42.
   Web of Science ®Google Scholar
• Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 2009;182(3):881–886.
   PubMed Web of Science ®Google Scholar
• Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859–864.
   PubMed Web of Science ®Google Scholar
• Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28(9):1502–1507.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Takagi T, et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol. 2015;194(2):297–303.
   PubMed Web of Science ®Google Scholar
• Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010;106(9):1270–1276.
   PubMed Web of Science ®Google Scholar
• Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014;66(5):874–880.
   PubMed Web of Science ®Google Scholar
• Bindayi A, Hamilton ZA, Mcdonald ML, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol. 2018;36(1):31–37.
   PubMed Web of Science ®Google Scholar
• Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–852.
   PubMed Web of Science ®Google Scholar
• Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008–2016.
   PubMed Web of Science ®Google Scholar
• Haas NB, Manola J, Dutcher JP, et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol. 2017;3(9):1249–1252.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Rj M, Hs P, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–2254.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Sunitinib NDA 21-938 and 21-968 approval letter. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_Approv.pdf
   Google Scholar
• Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;35(35):3916–3923.
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment for renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29(12):2371-2378.
   Google Scholar
• Figlin RA, Leibovich BC, Stewart GD, et al. Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? Ann Oncol. 2018;29(2):324–331.
   PubMed Web of Science ®Google Scholar
• Casuscelli J, Hsieh JJ. Are we ready for adjuvant sunitinib in high-risk renal cell Carcinoma? Eur Urol. 2018;73(1):69–70.
   PubMed Web of Science ®Google Scholar
• Sun M, Marconi L, Eisen T, et al. Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: a systematic review and pooled analysis. Eur Urol. 2018;74(5):611–620.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Martini JF, et al. Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase iii trial of adjuvant sunitinib. Clin Cancer Res off J Am Assoc Cancer Res. 2018;24(18):4407–4415.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–1076.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Center. Kidney Cancer, Version 2.2019. [cited Oct 20 2018]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
   Google Scholar
• You D, Jeong IG, Ahn JH, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011;185(1):54–59.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–66.
   PubMed Web of Science ®Google Scholar
• Psutka SP, Kim SP, Gross CP, et al. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization. Urology. 2015;85(2):442–450.
   PubMed Web of Science ®Google Scholar
• Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–427.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Cytoreductive nephrectomy - patient selection is key. N Engl J Med. 2018;379(5):481–482.
   PubMedGoogle Scholar
• Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2018.
   Google Scholar
• Macleod LC, Odisho AY, Tykodi SS, et al. Comparative effectiveness of initial surgery vs initial systemic therapy for metastatic kidney cancer in the targeted therapy era: analysis of a population-based Cohort. Urology. 2018;113:146–152.
   PubMed Web of Science ®Google Scholar
• Bhindi B, Habermann EB, Mason RJ, et al. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. J Urol. 2018;200(3):528–534.
   Google Scholar